Chelsea McLean

发表

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study

M. McElrath, S. D. De Rosa, M. Pau, 2022, PloS one.

Randomized Trial of Vaccines for Zaire Ebola Virus Disease.

S. Lees, D. Watson-Jones, P. Piot, 2022, The New England journal of medicine.

Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory

D. Watson-Jones, O. Anzala, S. Sirima, 2023, EBioMedicine.

Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo.

B. Hejblum, R. Thiébaut, L. Richert, 2023, Cell reports.

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans

H. Schuitemaker, Yvonne Wollmann, R. Roozendaal, 2023, Frontiers in immunology.

Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

M. Prague, V. Bockstal, M. Douoguih, 2023, NPJ vaccines.

Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial

Auguste Gaddah, M. Douoguih, Babajide Keshinro, 2024, Human vaccines & immunotherapeutics.

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.

D. Watson-Jones, E. D’Ortenzio, D. Ishola, 2023, The Lancet. Global health.

Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.

D. Watson-Jones, P. Kaleebu, O. Anzala, 2023, Vaccine.

Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo

N. Hens, P. van Damme, J. Matangila, 2023, The Journal of infectious diseases.